Related Experiment Video
Updated: Feb 6, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy
Paola Cassis1, Monica Locatelli1, Domenico Cerullo1
1IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso, Bergamo, Italy.
Abstract:
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have pleiotropic properties beyond blood glucose-lowering effects and modify important nonglycemic pathways, leading to end-organ protection. SGLT2 inhibitors display renoprotective effects in diabetic kidney disease, which creates a rationale for testing the therapeutic potential of this drug class in nondiabetic chronic kidney disease. Here, we have shown that dapagliflozin provided glomerular protection in mice with protein-overload proteinuria induced by bovine serum albumin (BSA), to a similar extent as an ACE inhibitor used as standard therapy for comparison. Dapagliflozin limited proteinuria, glomerular lesions, and podocyte dysfunction and loss. We provide the observation that SGLT2 was expressed in podocytes and upregulated after BSA injections. Through in vitro studies with cultured podocytes loaded with albumin we have identified what we believe to be a novel mechanism of action for SGLT2 inhibitor that directly targets podocytes and relies on the maintenance of actin cytoskeleton architecture. Whether SGLT2 inhibitors represent a possible future therapeutic option for some patients with proteinuric glomerular disease who do not have as yet an effective treatment will require ad hoc clinical studies.
Insights
Sodium-glucose cotransporter 2 (SGLT2) inhibitors like dapagliflozin protect glomeruli from protein overload. This study reveals a novel mechanism where SGLT2 inhibitors maintain podocyte actin structure, suggesting potential for non-diabetic kidney disease.
Area of Science:
- Nephrology
- Pharmacology
- Cell Biology
Background:
- Sodium-glucose cotransporter 2 (SGLT2) inhibitors offer benefits beyond glucose control, including organ protection.
- Renoprotective effects of SGLT2 inhibitors in diabetic kidney disease suggest potential in non-diabetic chronic kidney disease.
Purpose of the Study:
- To investigate the renoprotective effects of dapagliflozin in a mouse model of protein-overload proteinuria.
- To explore the underlying mechanism of SGLT2 inhibitor action on podocytes.
Main Methods:
- Protein-overload proteinuria was induced in mice using bovine serum albumin (BSA).
- Mice were treated with dapagliflozin or an ACE inhibitor as a control.
- In vitro studies used cultured podocytes exposed to albumin to investigate SGLT2 function and mechanism.
Main Results:
- Dapagliflozin significantly limited proteinuria, glomerular lesions, and podocyte dysfunction/loss.
- SGLT2 expression was observed in podocytes and upregulated following BSA injection.
- A novel mechanism involving the maintenance of actin cytoskeleton architecture by SGLT2 inhibitors in podocytes was identified.
Conclusions:
- Dapagliflozin demonstrates glomerular protective effects in proteinuric kidney injury, comparable to ACE inhibitors.
- SGLT2 inhibitors may offer a direct therapeutic benefit to podocytes via actin cytoskeleton stabilization.
- Further clinical studies are warranted to evaluate SGLT2 inhibitors for proteinuric glomerular diseases without current effective treatments.
Related Concept Videos
Limiting Reactant
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
The Number e as a Limit
Types of Limits I
Limit Laws I
Limits at Infinity

